Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation

Korea University

Status: Unknown

Conditions: Atrial Fibrillation

Treatments: Drug: warfarin

Study type: Interventional

Funder types: Other

Identifiers

NCT01991951

KUMCEP01

Details and patient eligibility

About

We hypothesized that in patients with low CHADS-VASc score (2 or < 2), there is no difference in thromboembolic or bleeding events between patients with short term warfarin therapy (2 weeks after catheter ablation) and conventional therapy (3 weeks before and 8 weeks after procedure).

Enrollment: 520 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with paroxysmal atrial fibrillation who underwent radiofrequency catheter ablation
• Patients with CHADS-VASc score 2 or less than 2

Exclusion criteria

• Patients who do not consent to the study
• Permanent or persistent atrial fibrillation
• Patients who have underwent prior catheter ablation for atrial fibrillation
• CHADS-VASc score more than 2
• History of stroke
• LVEF <40%
• Significant liver or kidney dysfunction
• History of major bleeding during warfarin therapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

520 participants in 2 patient groups

Short term warfarin group

Experimental group

Description:

taking warfarin for only 2 weeks after catheter ablation of atrial fibrillation

Treatment:

Drug: warfarin

Conventional therapy arm

Active Comparator group

Description:

conventional warfarin therapy of 3 weeks before and 8 weeks after catheter ablation of AF

Treatment:

Drug: warfarin